Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymfactin in Combination With Surgical Lymph Node Transfer for Secondary Lymphedema
NCT03658967Phase 2Completed
- Sponsor
- Herantis Pharma
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in secondary lymphedema comparing Lymfactin with Placebo (2 arms). Primary endpoints: Measurement of the volume of the arms at 24 Months, Measurement of the lymphatic flow of the affected arm by quantitative lymphoscintigraphy at 24 Months and 1 more. Started Jun 2018; status: completed.
02
Drugs
lymfactin
03
Conditions
secondary lymphedema
Beyond the preview
Go deeper on NCT03658967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658967.